1837-55-4

Basic information

• Product Name: 3,5-Dichloropyridazine
• Synonyms: 3,5-Dichloropyridazine;SA029519;Pyridazine,3,5-dichloro-
• CAS NO: 1837-55-4
• Molecular Formula: C₄H₂Cl₂N₂
• Molecular Weight: 148.98
• Mol File: 1837-55-4.mol

Chemical Properties

• Melting Point: 60.0 to 64.0 °C
• Boiling Point: 280.8 °C at 760 mmHg
• Flash Point: 150.5 °C
• Appearance: /
• Density: 1.493 g/cm³
• Vapor Pressure: 0.00629mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: DMSO (Sparingly), Methanol (Slightly)
• PKA: -0.25±0.10(Predicted)
• CAS DataBase Reference: 3,5-Dichloropyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dichloropyridazine(1837-55-4)
• EPA Substance Registry System: 3,5-Dichloropyridazine(1837-55-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 1837-55-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,5-Dichloropyridazine is used as a novel histamine H4 antagonist for the treatment of asthma and allergy. Its ability to block the histamine H4 receptor helps in reducing inflammation and other allergic symptoms, providing relief to patients suffering from these conditions.
Additionally, 3,5-Dichloropyridazine has potential antinociceptive and anti-inflammatory effects, which can be beneficial in managing pain and inflammation associated with various conditions. Further research and development are needed to fully understand and harness the therapeutic potential of this compound in the pharmaceutical industry.

InChI:InChI=1/C4H2Cl2N2/c5-3-1-4(6)8-7-2-3/h1-2H

Upstream product

• 1081808-80-1 (Z)-2,4,4,4-tetrachlorobut-2-enal 
• 19429-51-7 2,4,4,4-tetrachloro-but-2-enal 

Downstream Products

• 697739-36-9 5-chloro-3-(4-fluorophenyl)pyridazine 
• 1314978-36-3 5-chloropyridazin-3-amine 
• 1366234-53-8 C₁₆H₁₁Cl₂N₃O 
• 1383481-12-6 N-(5-chloropyridazin-3-yl)-1,1-diphenylmethanimine 
• 123696-02-6 3-chloro-5-methoxy-pyridazine 
• 1026-46-6 3,5-Diphenylpyridazine 
• 1426548-41-5 5-chloro-3-phenylpyridazine 
• 86663-08-3 3-chloro-5-phenyl-pyridazine 
• 1448295-38-2 C₁₁H₉ClN₂ 
• 1448295-25-7 C₁₁H₉ClN₂ 
• 1448295-39-3 C₁₁H₉ClN₂ 
• 1448295-26-8 C₁₁H₉ClN₂ 
• 1448295-40-6 C₁₂H₉ClN₂O 
• 1448295-27-9 C₁₂H₉ClN₂O 

Relevant articles and documents

Energetic Functionalization of the Pyridazine Scaffold: Synthesis and Characterization of 3,5-Diamino-4,6-dinitropyridazine-1-Oxide

The synthesis of 3,5-diamino-4,6-dinitropyridazine-1-oxide (8) is reported. It is prepared in a six-step synthetic procedure starting from acyclic compounds, and shows good properties (detonation velocity DC–J = 8486 m s–1, detonation pressure pC–J = 302 kbar), and sensitivity toward mechanical stimuli. Compound 8 and its precursor (7, 3,5-dimethoxy-4,6-dinitropyridazine-1-oxide) were characterized by means of multinuclear (1H, 13C, 14N, 15N) NMR spectroscopy, mass spectrometry, vibrational spectroscopy (IR and Raman), elemental analysis and differential thermal analysis (DTA) measurements. Compounds 4, 5, 6, 7, 8 and 9 were also characterized by low-temperature single-crystal X-ray diffraction. The heats of formation for 7 and 8 were calculated using the atomization method based on CBS-4M enthalpies. Using the experimentally determined (X-ray) densities and the calculated standard molar enthalpies of formation, several detonation parameters such as the detonation pressure, energy and velocity were predicted by using the EXPLO5 code (V6.03). The sensitivities of 3,5-dimethoxy-4,6-dinitropyridazine-1-oxide (7) and 3,5-diamino-4,6-dinitropyridazine-1-oxide (8) toward impact, friction and electrical discharge were tested according to BAM standards. In addition, the shock reactivity of 8 was measured by applying the small-scale shock reactivity test, showing similar values to HNS, PYX and TKX-55.

The Pyridazine Scaffold as a Building Block for Energetic Materials: Synthesis, Characterization, and Properties

In the present studies, the synthesis of new energetic materials based on the pyridazine scaffold and their characterization is the main subject. For this purpose, desired 3,5-dimethoxy-4,6-dinitropyridazine-1-oxide (7) was synthesized in the first instance. The persubstituted pyridazine precursor laid the groundwork for further preparative modification. The targeted functionalization through the regioselective introduction of various smaller amine nucleophiles such as methylamine or 2-aminoethanol gave several new energetic materials. Among them are 3,5-bis(methylamino)-4,6-dinitropyridazine-1-oxide (8), 3,5-bis(methylnitramino)-4,6-dinitropyridazine-1-oxide (9), 3,5-bis(dimethylamino)-4,6-dinitropyridazine-1-oxide (10), and 3,5-bis((2-hydroxyethyl)amino)-4,6-dinitropyridazine-1-oxide (11). With the aim of increasing the detonation performance, compound 8 was additionally nitrated and 3,5-bis(methylnitramino)-4,6-dinitropyridazine-1-oxide (9) was obtained. These new energetic materials were characterized and identified by multinuclear NMR (1H, 13C, 14N, 15N) and IR spectroscopy, elemental analysis and mass spectrometry. In addition, their sensitivities toward impact, friction and electrostatic discharge were thoroughly examined. Furthermore, obtained single-crystals of the substances were characterized by low-temperature single-crystal X-ray diffraction.

GPR52 MODULATOR COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1): (1) and salts thereof, wherein R1, Q, X, Y and Z are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.

AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN

the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C-Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C-Ar2, with the proviso that when Y is N or CH then Z is C-Ar2, and with the further proviso that when Y is C-Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CONR3R4, NR3SO2R6, SO2NR3R4, -(CH2)mcarboxy, esterified -(CH2)mcarboxy or -(CH2)mNR3R4; R2 represents hydrogen, halogen, hydroxy, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; R3 and R4 are each independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or fluoroC1-6alkyl; or R3 and R4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)2, or NR5; R5 represents hydrogen, C1-4alkyl, hydroxyC1-4alkyl or C1-4alkoxyC1-4alkyl; R6 represents hydrogen, C1-6alkyl, fluoroC1-6alkyl, C3-7cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.